# A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance

> **NCT01751984** · PHASE2 · COMPLETED · sponsor: **Esperion Therapeutics, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** ETC-1002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01751984
- **Lead sponsor:** Esperion Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-04
- **Primary completion:** 2013-05-01
- **Final completion:** 2013-05-01
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01751984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01751984, "A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01751984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*